+

WO2007109118A3 - Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique - Google Patents

Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique Download PDF

Info

Publication number
WO2007109118A3
WO2007109118A3 PCT/US2007/006611 US2007006611W WO2007109118A3 WO 2007109118 A3 WO2007109118 A3 WO 2007109118A3 US 2007006611 W US2007006611 W US 2007006611W WO 2007109118 A3 WO2007109118 A3 WO 2007109118A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant human
rhccio
treatment
rhcc10
respiratory disorders
Prior art date
Application number
PCT/US2007/006611
Other languages
English (en)
Other versions
WO2007109118A2 (fr
WO2007109118A9 (fr
Inventor
Aprile L Pilon
Original Assignee
Cc 10 Sweden Ab
Aprile L Pilon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cc 10 Sweden Ab, Aprile L Pilon filed Critical Cc 10 Sweden Ab
Publication of WO2007109118A2 publication Critical patent/WO2007109118A2/fr
Publication of WO2007109118A3 publication Critical patent/WO2007109118A3/fr
Publication of WO2007109118A9 publication Critical patent/WO2007109118A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de manière générale l'utilisation d'une CC10 humaine recombinante (rhCC10), également appelée utéroglobine humaine recombinante, utilisée en tant qu'agent thérapeutique dans le traitement du syndrome de détresse respiratoire (RDS), de la dysplasie broncho-pulmonaire (BPD), de la maladie pulmonaire chronique et/ou de la fibrose pulmonaire, de l'asthme et de la maladie pulmonaire obstructive chronique (COPD). Plus particulièrement, cette invention concerne des procédés, contenant largement les niveaux de dosage critiques de la rhCC10, pouvant être administrée de façon sécurisée et efficace en vue de traiter les états pathologiques susmentionnés. L'invention concerne enfin une composition utile dans l'administration de la rhCC10 à des êtres humains.
PCT/US2007/006611 2006-03-16 2007-03-16 Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique WO2007109118A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/378,798 2006-03-16
US11/378,798 US20060281681A1 (en) 1997-05-28 2006-03-16 Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease

Publications (3)

Publication Number Publication Date
WO2007109118A2 WO2007109118A2 (fr) 2007-09-27
WO2007109118A3 true WO2007109118A3 (fr) 2007-11-08
WO2007109118A9 WO2007109118A9 (fr) 2007-12-27

Family

ID=38522965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006611 WO2007109118A2 (fr) 2006-03-16 2007-03-16 Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique

Country Status (2)

Country Link
US (5) US20060281681A1 (fr)
WO (1) WO2007109118A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
NZ599928A (en) * 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
NZ588895A (en) * 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
JP5944316B2 (ja) * 2009-10-15 2016-07-05 セラブロン セラピューティクス，インコーポレイテッド インフルエンザ処置用の組換え型ヒトｃｃ１０タンパク質
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
WO2012170842A2 (fr) 2011-06-09 2012-12-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide destiné à la protection contre des troubles respiratoires allergiques
WO2013142387A1 (fr) * 2012-03-19 2013-09-26 Cardiomems, Inc. Surveillance hémodynamique artérielle pulmonaire pour l'évaluation d'une bronchopneumopathie chronique obstructive et son traitement
RU2506897C1 (ru) * 2012-07-27 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки тяжести острой дыхательной недостаточности у новорожденных, находящихся на респираторной поддержке
EP2922465A4 (fr) 2012-11-21 2016-07-06 Cardiomems Inc Dispositifs, systèmes et méthodes d'évaluation et de traitement de l'hypertension artérielle pulmonaire (htap)
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
WO2014145712A1 (fr) 2013-03-15 2014-09-18 Cardiomems, Inc. Méthodes de traitement d'états cardiovasculaires
GB201403605D0 (en) * 2014-02-28 2014-04-16 Mologic Ltd Monitoring inflammation status
WO2016133560A1 (fr) * 2015-02-16 2016-08-25 Therabron Therapeutics, Inc. Protéine cc10 humaine recombinante pour le traitement de la grippe et de l'ebola
WO2016205430A1 (fr) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Protéine cc10 humaine recombinée facilitant la réparation de l'épithélium respiratoire et le protégeant contre les dommages dus à l'exposition tant à la fumée de cigarette qu'à d'autres fumées
WO2020113232A1 (fr) * 2018-11-30 2020-06-04 Apc Research Assets Llc Compositions et méthodes d'utilisation de sécrétoglobines pour protéger le glycocalyx par l'intermédiaire d'interactions avec des protéines de protéoglycane à héparane sulfate

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
WO1987002367A2 (fr) * 1985-10-18 1987-04-23 The Upjohn Company Hydrocarbures cycliques avec chaine laterale aminoalkyle
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
SE461616B (sv) 1987-05-08 1990-03-05 Biocarb Ab Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5354269A (en) * 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
BE1006919A3 (nl) 1993-03-15 1995-01-24 Ley Marc Jozef Philemon De Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum.
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
FR2724665B1 (fr) 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
WO1997001627A1 (fr) 1995-06-27 1997-01-16 Igen International, Inc. Forte expression de proteines de fusion impliquant l'ubiquitine et recuperation efficace de celles-ci a partir d'escherichia coli
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
CA2248136A1 (fr) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Facteur i, ii et iii de liaison de steroides specifique a l'endometre humain
AU5253998A (en) * 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
DE19709373A1 (de) 1997-03-07 1998-09-10 Manfred Veenker Leitung für gefährdende Fluide und Verfahren zu deren Herstellung
US20020160948A1 (en) * 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20050261180A1 (en) * 1997-05-28 2005-11-24 Pilon Aprile L Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20030207795A1 (en) * 1997-05-28 2003-11-06 Pilon Aprile L. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) * 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US6255281B1 (en) * 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20020169108A1 (en) * 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
PL343770A1 (en) 1998-04-16 2001-09-10 Texas Biotechnology Corp N,n-disubstituted amides that inhibit the binding of integrins to their receptors
WO2000072868A2 (fr) 1999-06-01 2000-12-07 Prendergast Patrick T Peptides a usage therapeutique
CN1115102C (zh) 1999-07-30 2003-07-23 北京红缔康华生物工程技术有限公司 一种生物催化剂的制作方法和所制成的生物催化剂及用途
EP1235846A4 (fr) * 1999-11-04 2004-07-14 Human Genome Sciences Inc Polynucleotides, polypeptides, et anticorps analogues a l'uteroglobine
AU2001282977A1 (en) * 2000-07-26 2002-02-05 The Burnham Institute Screening methods based on superactivated alphavbeta3 integrin
US20090227025A1 (en) * 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
CA2719923A1 (fr) * 2008-04-08 2009-10-15 Amyris Biotechnologies, Inc. Expression de sequences heterologues
NZ588895A (en) * 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
JP5944316B2 (ja) 2009-10-15 2016-07-05 セラブロン セラピューティクス，インコーポレイテッド インフルエンザ処置用の組換え型ヒトｃｃ１０タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEVINE C.R. ET AL.: "Safety, Pharmacokinetics, and Anti-inflammatory Effects of Intratracheal Recombinant Human Clara Cell Protein in Premature Infants with Respiratory Distress Syndrome", PEDIATR. RES., vol. 58, no. 1, July 2005 (2005-07-01), pages 15 - 21, XP008148069, DOI: doi:10.1203/01.PDR.0000156371.89952.35 *
SHASHIKANT B.N. ET AL.: "Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome; physiological inflammatory, and kinetic profiles", J. APPL. PHYSIOL., vol. 99, no. 6, 4 August 2005 (2005-08-04), pages 2204 - 2211, XP008067058, DOI: doi:10.1152/japplphysiol.00246.2005 *

Also Published As

Publication number Publication date
US20110183887A1 (en) 2011-07-28
US20060281681A1 (en) 2006-12-14
US7846899B2 (en) 2010-12-07
WO2007109118A2 (fr) 2007-09-27
US20090197808A1 (en) 2009-08-06
US20130261047A1 (en) 2013-10-03
US20160243193A1 (en) 2016-08-25
WO2007109118A9 (fr) 2007-12-27
US8470767B2 (en) 2013-06-25

Similar Documents

Publication Publication Date Title
WO2007109118A3 (fr) Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique
WO2007082068A3 (fr) Procedes et compositions pour le traitement de l’asthme chez les primates humains et non humains
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
IL183696A0 (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
MXPA02011311A (es) Composicion novedosa.
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
RS20050484A (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
NZ592839A (en) Treatment of diseases, disorders or conditions of the lung using placental cells
PT1326595E (pt) Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
GB0008660D0 (en) The treatment of respiratory diseases
CO5550426A2 (es) Novedoso metodo terapeutico
RS76704A (en) Formoterol superfine formulation
WO2003079992A3 (fr) Apport pulmonaire de levodopa
WO2008024843A3 (fr) Méthode de thérapie combinatoire pour le traitement d'une infection par le virus de l'hépatite c et compositions pharmaceutiques correspondantes
WO2010068754A3 (fr) Procédés et compositions pour la délivrance de médicaments aux poumons
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
WO2009019598A3 (fr) Thérapie par inhalation pour des troubles respiratoires
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
MXPA04012728A (es) Deshidroepiandrosterona dihidratada y metodos para el tratamiento de asma o una enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
SE9900833D0 (sv) Novel combination
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
WO2007046113A3 (fr) Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
SE9900834D0 (sv) Novel combination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753254

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07753254

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载